Re: Renal replacement therapy: summary of NICE guidance
It's striking that the UK has half the incidence of end-stage renal disease than the US. I'm also impressed that the majority of the UK's ESRD patients are transplanted which I agree is the best treatment for ESRD. Prevention, of course, would be even better. What the article failed to reference is that 90% of dialysis has been preventable since 2002 (1). If that were known (2), there would be no waiting list at all for a cadaver kidney transplant in either the UK or the US. There would be no need for living donors, and both countries could be dialysis-free within 5 years.
In acute renal therapy, it's also possible to avoid renal replacement therapy (RRT) (3).
References
1. Paper #1 at www.genomed.com/publications (abstract at PubMed ID: 12396747)
2. Paper #9 at www.genomed.com/publications
3. https://patents.google.com/patent/US6998404B2/en
Competing interests:
I am the Founder, CEO, and majority shareholder of GenoMed, Inc, a NextGen Disease Management company that uses genomics to solve diseases. We use knowledge of disease-causing genes to improve prediction and treatment of common diseases like kidney failure. We repurpose already existing drugs whenever possible.
Rapid Response:
Re: Renal replacement therapy: summary of NICE guidance
It's striking that the UK has half the incidence of end-stage renal disease than the US. I'm also impressed that the majority of the UK's ESRD patients are transplanted which I agree is the best treatment for ESRD. Prevention, of course, would be even better. What the article failed to reference is that 90% of dialysis has been preventable since 2002 (1). If that were known (2), there would be no waiting list at all for a cadaver kidney transplant in either the UK or the US. There would be no need for living donors, and both countries could be dialysis-free within 5 years.
In acute renal therapy, it's also possible to avoid renal replacement therapy (RRT) (3).
References
1. Paper #1 at www.genomed.com/publications (abstract at PubMed ID: 12396747)
2. Paper #9 at www.genomed.com/publications
3. https://patents.google.com/patent/US6998404B2/en
Competing interests: I am the Founder, CEO, and majority shareholder of GenoMed, Inc, a NextGen Disease Management company that uses genomics to solve diseases. We use knowledge of disease-causing genes to improve prediction and treatment of common diseases like kidney failure. We repurpose already existing drugs whenever possible.